

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC., APOTEX CORP., and
ARGENTUM PHARMACEUTICALS LLC,
Petitioners,
v.
NOVARTIS AG,
Patent Owner.

Case IPR2017-00854¹
U.S. Patent No. 9,187,405

PATENT OWNER'S EXHIBIT LIST

Mail Stop Patent Board
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

¹ Case IPR2017-01550 has been joined with this proceeding.

List of Patent Owner's Evidence and Exhibits

Exhibit	Reference
2001	Declaration of Robert W. Trenchard in Support of Motion for Admission <i>Pro Hac Vice</i>
2002	Order Admitting Robert W. Trenchard <i>Pro Hac Vice</i> , <i>Torrent Pharm. Ltd. v. Novartis AG</i> , IPR2014-00784, Paper 8
2003	Declaration of Fred D. Lublin, M.D. in support of Patent Owner's Preliminary Response
2004	Curriculum Vitae of Fred D. Lublin, M.D.
2005	Declaration of William J. Jusko, Ph.D. in support of Patent Owner's Preliminary Response
2006	Curriculum Vitae of William J. Jusko, Ph.D.
2007	United States Patent 5,604,229 to Fujita et al.
2008	Brinkmann et al., <i>The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors</i> , 277 <i>J. Bio. Chem.</i> 24, 21453–57 (2002)
2009	Forrest et al., <i>Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes</i> , 309 <i>J. Pharm. And Experimental Therapeutics</i> 2, 758–68 (2004)
2010	Lublin et al., <i>Defining the clinical course of multiple sclerosis: Results of an international survey</i> , 46 <i>Neurology</i> 907–11 (1996)
2011	Miller et al., <i>How Modeling and Simulation Have Enhanced Decision Making in New Drug Development</i> , 32 <i>J. Pharmacokinetics and Pharmacodynamics</i> 2, 185–97 (2005)
2012	Sanna et al., <i>Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P₁ and S1P₃, Respectively, Regulate Lymphocyte Recirculation and Heart Rate</i> , 279 <i>J. Bio. Chem.</i> 14, 13839–48 (2004)
2013	Public LinkedIn Profile of Tadimeti S. Rao, Ph.D.
2014	Webb et al., <i>Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice</i> , 153 <i>J. Neuroimmunology</i> 108–21 (2004)
2015	U.S. Food and Drug Administration Guidance – “Guidance for Industry End-of-Phase 2A Meetings,” accessed on March 30, 2009 at https://www.fda.gov/Error/index.htm .
2016	U.S. Food and Drug Administration Guidance – “Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products – Content and Format,” (December 2016)

Exhibit	Reference
2017	Bloomberg Profile of Klemens Budde, M.D., accessed on April 27, 2017 at http://www.bloomberg.com
2018	Public LinkedIn Profile of Janet Karlix
2019	Bibliographic Data of Application No. 06/633,481, accessed on May 1, 2017 at portal.uspto.gov/pair/PublicPair
2020	Transcript of August 25, 2017, conference call between the parties and the Board regarding Patent Owner's List of Proposed Motions.

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 4.26, I hereby certify that on August 30, 2017, a true and accurate copy of PATENT OWNER'S EXHIBIT LIST was served via electronic mail, by agreement of the parties, on the following counsel of record for Petitioners:

For Apotex:

Steven W. Parmelee: sparmelee@wsgr.com
Michael T. Rosato: mrosato@wsgr.com
Jad. A. Mills: jmills@wsgr.com

Wilson Sonsini Goodrich & Rosati
701 Fifth Avenue, Suite 5100
Seattle, WA 98104
Telephone: 206-883-2542

For Argentum:

Teresa Stanek Rea: trea@crowell.com
Deborah H. Yelling: dyelling@crowell.com
Shannon M. Lentz: slentz@crowell.com
Tyler C. Liu: TLiu@agpharm.com

Crowell & Moring LLP
Intellectual Property Group
1001 Pennsylvania Ave, NW
Washington, DC 20004-2595
(202) 624-2620

Dated: August 30, 2017

/Jane M. Love, Ph.D./
Jane M. Love, Ph.D.
Reg. No. 42,812
Lead Counsel for Patent Owners
Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, New York 10166-0193
jlove@gibsondunn.com
Tel: 212-351-3922